ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives

Core Insights - Telix Pharmaceuticals Limited has announced that Part 1 of the ProstACT Global Phase 3 study for TLX591-Tx has met its primary objectives, showing an acceptable safety and tolerability profile with no new safety signals observed [1][4]. Study Findings - Part 1 confirmed the safety profile, biodistribution, and dosimetry of TLX591-Tx administered in two doses, 14 days apart, alongside standard of care therapies: abiraterone, enzalutamide, or docetaxel, in patients with metastatic castration-resistant prostate cancer (mCRPC) [2][6]. - The study dosed 36 patients across three cohorts, with no adverse drug-drug interactions observed in TLX591-Tx combinations [5][6]. - Hematologic events were transient and manageable, aligning with expectations for this therapeutic class, with Grade 3 thrombocytopenia at 14% and neutropenia at 22% [14]. Trial Design and Progress - The ProstACT Global trial is a differentiated Phase 3 study comparing PSMA-targeted Lu-rADC therapy with standard of care versus standard of care alone, reflecting current clinical practices [3]. - Telix has advanced to Part 2 of the study, which involves a 2:1 randomized treatment expansion, pending regulatory approval in various jurisdictions [3][23]. Expert Commentary - Dr. Neeraj Agarwal emphasized the feasibility of integrating TLX591-Tx with current therapies for mCRPC, noting that adverse events were consistent with the patient population and resolved quickly [4]. - Dr. David N. Cade highlighted the need for improved treatment options for advanced prostate cancer and expressed optimism about TLX591-Tx's potential as a first-line option [4]. Dosimetry and Pharmacology - The dosimetry profile indicated no significant acute or delayed kidney toxicity, as TLX591-Tx is primarily cleared through the liver, minimizing adverse effects commonly associated with other PSMA-targeted therapies [10]. - The pharmacokinetics demonstrated sustained activity at 15 days, corroborated by imaging showing prolonged tumor retention [14].